MyAverix Finance
AU · Healthcare
Nexalis Therapeutics Ltd (NX1)
Biotechnology
Nexalis Therapeutics Ltd (NX1) is listed on AU in the Healthcare sector. Industry: Biotechnology. As of 2026-03-23, reported P/E ratio is 18.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.
Key metrics for NX1
Nexalis Therapeutics Ltd (NX1) — FAQ
What is NX1's P/E ratio?
The price-to-earnings (P/E) ratio for Nexalis Therapeutics Ltd (NX1) is 18.00 (data as of 2026-03-23).
Does Nexalis Therapeutics Ltd pay a dividend?
Dividend yield is not available in the current snapshot for Nexalis Therapeutics Ltd (NX1). Check the MyAverix Finance app for the latest dividend data.
What sector is Nexalis Therapeutics Ltd in?
Nexalis Therapeutics Ltd (NX1) is classified in the Healthcare sector (Biotechnology industry).
What exchange is NX1 listed on?
NX1 is listed on AU.
Full report in the app
Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.